Search

Your search keyword '"Arantxa González"' showing total 251 results

Search Constraints

Start Over You searched for: Author "Arantxa González" Remove constraint Author: "Arantxa González"
251 results on '"Arantxa González"'

Search Results

51. Increased Serum Procollagen type I C-terminal Propeptide Levels are Associated with Left Ventricular Dysfunction in Patients Treated with Anthracycline-based Cancer Chemotherapy

52. Myocardial fibrosis in asymptomatic and symptomatic chronic severe primary mitral regurgitation and relationship to tissue characterisation and left ventricular function on cardiovascular magnetic resonance

53. A novel treatment for heart failure targets myocardial fibrosis

54. Abstract 15710: Myocardial Ischaemia in Cardiac Amyloidosis, Changing Perspectives

55. 1 Invasive and non-invasive quantification of myocardial fibrosis in primary mitral regurgitation: prognostic implications for post-operative remodelling, symptom burden and exercise capacity

56. H3K27ac acetylome signatures reveal the epigenomic reorganization in remodeled non-failing human hearts

57. P1309RIGHT VENTRICULAR-PULMONARY ARTERIAL UNCOUPLING IN PATIENTS ON CHRONIC HEMODIALYSIS WITH SEVERE RIGHT VENTRICULAR REMODELING

58. Author Correction: MicroRNA-19b is a potential biomarker of increased myocardial collagen cross-linking in patients with aortic stenosis and heart failure

60. Role of Cardiac Lymphatics in Myocardial Edema and Fibrosis: JACC Review Topic of the Week

61. Natural Compound Library Screening Identifies New Molecules for the Treatment of Cardiac Fibrosis and Diastolic Dysfunction

62. Plasma protein biomarkers and their association with mutually exclusive cardiovascular phenotypes: the FIBRO‑TARGETS case–control analyses

63. Does chronic kidney disease facilitate malignant myocardial fibrosis in heart failure with preserved ejection fraction of hypertensive origin?

64. Microvascular and lymphatic dysfunction in HFpEF and its associated comorbidities

65. Myocardial Remodeling in Hypertension

66. Omics phenotyping in heart failure: the next frontier

67. Biomarker-based phenotyping of myocardial fibrosis identifies patients with heart failure with preserved ejection fraction resistant to the beneficial effects of spironolactone: results from the Aldo-DHF trial

68. Osteoglycin prevents the development of age-related diastolic dysfunction during pressure overload by reducing cardiac fibrosis and inflammation

69. MicroRNA-221/222 Family Counteracts Myocardial Fibrosis in Pressure Overload-Induced Heart Failure

70. Reverse Myocardial Remodeling Following Valve Replacement in Patients With Aortic Stenosis

71. Role of Myocardial Collagen in Severe Aortic Stenosis With Preserved Ejection Fraction and Symptoms of Heart Failure

72. Papel del colágeno miocárdico en la estenosis aórtica grave con fracción de eyección conservada y síntomas de insuficiencia cardiaca

73. Phenotyping of myocardial fibrosis in hypertensive patients with heart failure. Influence on clinical outcome

74. Myocardial fibrosis: biomedical research from bench to bedside

75. The Hypertensive Myocardium

76. Increased Fibroblast Growth Factor 23 in Heart Failure: Biomarker, Mechanism, or Both?

77. Proteomic Bioprofiles and Mechanistic Pathways of Progression to Heart Failure The HOMAGE Study

78. Proteomic Bioprofiles and Mechanistic Pathways of Progression to Heart Failure

79. Association of left atrium voltage amplitude and distribution with the risk of atrial fibrillation recurrence and evolution after pulmonary vein isolation: An ultrahigh-density mapping study

80. CT-1 (Cardiotrophin-1)-Gal-3 (Galectin-3) Axis in Cardiac Fibrosis and Inflammation

81. Characterization of biventricular alterations in myocardial (reverse) remodelling in aortic bandinginduced chronic pressure overload

82. Circulating Biomarkers Predicting Longitudinal Changes in Left Ventricular Structure and Function in a General Population

83. ST2 in Heart Failure

84. The Role of Circulating Biomarkers in Peripheral Arterial Disease

85. Association of cystatin C with heart failure with preserved ejection fraction in elderly hypertensive patients

86. Myocardial Collagen Cross-Linking Is Associated With Heart Failure Hospitalization in Patients With Hypertensive Heart Failure

87. 14P Comparison of the predictive power of survival of the Royal Marsden Score, the GRIM score and the LIPI score in phase I trial patients

88. Reprint of 'The complex dynamics of myocardial interstitial fibrosis in heart failure. Focus on collagen cross-linking'

89. The complex dynamics of myocardial interstitial fibrosis in heart failure. Focus on collagen cross-linking

90. Myocardial Remodeling in Hypertension

91. P6490Myocardial T2 in aortic stenosis: compensatory vasodilatation or subacute inflammation?

92. Evaluating Inclusivity using Quantitative Personas

93. Immunomodulation by adoptive regulatory T-cell transfer improves Coxsackievirus B3-induced myocarditis

94. Potential spironolactone effects on collagen metabolism biomarkers in patients with uncontrolled blood pressure

95. OBSOLETE: Hypertensive Heart Disease

96. Biomarker-based phenotyping of myocardial fibrosis identifies patients with heart failure with preserved ejection fraction resistant to the beneficial effects of spironolactone: results from the Aldo-DHF trial

97. p-SMAD2/3 and DICER promote pre-miR-21 processing during pressure overload-associated myocardial remodeling

98. Searching for new mechanisms of myocardial fibrosis with diagnostic and/or therapeutic potential

99. Circulating Biomarkers of Myocardial Fibrosis

100. Galectin-3 and histological, molecular and biochemical aspects of myocardial fibrosis in heart failure of hypertensive origin

Catalog

Books, media, physical & digital resources